Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 23, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 3,500,000 ordinary shares.
- Purchase Price: 1,265.64 pence per share.
- Treasury Shares Held: 459,964,158 shares (representing 8.27% of total voting rights).
- Shares in Issue: 5,564,785,013 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury shareholding following the October 23, 2007 transaction. The total number of shares held in Treasury now represents 8.27% of the total voting rights in the Company.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (3,500,000 shares at 1,265.64 pence) against the company's cash position in other filings.
- Confirm the updated share count of 5,564,785,013 for calculating ownership percentages under Disclosure and Transparency Rules.
- Note that the Treasury shareholding has reached 8.27% of total voting rights.